212200-57-2

Basic information

• Product Name: BENZYL 3-OXO-3-CYCLOPROPYLPROPIONATE
• Synonyms: BENZYL 3-OXO-3-CYCLOPROPYLPROPIONATE;Benzyl 3-cyclopropyl-3-oxopropanoate
• CAS NO: 212200-57-2
• Molecular Formula: C₁₃H₁₄O₃
• Molecular Weight: 218.251
• Mol File: 212200-57-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZYL 3-OXO-3-CYCLOPROPYLPROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 3-OXO-3-CYCLOPROPYLPROPIONATE(212200-57-2)
• EPA Substance Registry System: BENZYL 3-OXO-3-CYCLOPROPYLPROPIONATE(212200-57-2)

Safety Data

• Hazardous Substances Data: 212200-57-2(Hazardous Substances Data)

Upstream product

• 134302-11-7 5-(cyclopropanecarbonyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 100-51-6 benzyl alcohol 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 2033-24-1 cycl-isopropylidene malonate 
• 4023-34-1 cyclopropanecarboxylic acid chloride 

Downstream Products

• 1399841-33-8 (E)-benzyl 2-(cyclopropanecarbonyl)-6-oxohex-4-enoate 
• 1399841-15-6 (1S,4R,5S)-benzyl 5-cyclopropyl-7-oxo-6-oxabicyclo[3.2.0]heptane-4-carboxylate 

Relevant articles and documents

5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Bismuth(III) chloride-catalyzed highly efficient transesterification of β-keto esters

Bismuth(III) chloride was found to be an efficient catalyst for the transesterification of a variety of β-keto esters with a wide range of alcohols to afford transesterified products in good to high yields in short reaction times (see Table). Copyright

A3 adenosine receptor antagonists

Disclosed are pyridine and dihydropyridine derivatives, pharmaceutical compositions comprising one or more of these derivatives, and a method of selectively blocking an A3adenosine receptor of a mammal by the use of one or more of these derivatives. An example of the pyridine derivative is of the formula (I): wherein R2is ethyl, R3is ethylsulfanyl; R4is ethyl, propyl, or hydroxypropyl; R5is ethyl, propyl, fluoroethyl, or fluoropropyl; and R6is phenyl or fluorophenyl. The derivatives of the present invention can be used for inhibiting binding of ligands to an adenosine receptor. The derivatives also can be used for characterizing an adenosine receptor.

Structure-activity relationships and molecular modeling of 3,5-diacyl- 2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists

The structure-activity relationships of 6-phenyl-1,4-dihydropyridine derivatives as selective antagonists at human A3 adenosine receptors have been explored (Jiang et al. J. Med. Chem. 1997, 39, 4667-4675). In the present study, related pyridine derivatives have been synthesized and tested for affinity at adenosine receptors in radioligand binding assays. K(i) values in the nanomolar range were observed for certain 3,5-diacyl-2,4- dialkyl-6-phenylpyridine derivatives in displacement of [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyladenosine) at recombinant human A3 adenosine receptors. Selectivity for A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A(2A) receptors. Structure-activity relationships at various positions of the pyridine ring (the 3- and 5-acyl substituents and the 2- and 4-alkyl substituents) were probed. A 4-phenylethynyl group did not enhance A3 selectivity of pyridine derivatives, as it did for the 4-substituted dihydropyridines. At the 2-and 4-positions ethyl was favored over methyl. Also, unlike the dihydropyridines, a thioester group at the 3-position was favored over an ester for affinity at A3 adenosine receptors, and a 5-position benzyl ester decreased affinity. Small cycloalkyl groups at the 6-position of 4-phenylethynyl-1,4- dihydropyridines were favorable for high affinity at human A3 adenosine receptors, while in the pyridine series a 6-cyclopentyl group decreased affinity. 5-Ethyl 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5- carboxylate, 38, was highly potent at human A3 receptors, with a K(i) value of 20 nM. A 4-propyl derivative, 39b, was selective and highly potent at both human and rat A3 receptors, with K(i) values of 18.9 and 113 nM, respectively. A 6-(3-chlorophenyl) derivative, 44, displayed a K(i) value of 7.94 nM at human A3 receptors and selectivity of 5200-fold. Molecular modeling, based on the steric and electrostatic alignment (SEAL) method, defined common pharmacophore elements for pyridine and dihydropyridine structures, e.g., the two ester groups and the 6-phenyl group. Moreover, a relationship between affinity and hydrophobicity was found for the pyridines.